Ibuprofen is the Most Appropriate Acute Treatment
For this 18-year-old male with bilateral, moderate-intensity, "tight band" headaches occurring 2-3 times per week, ibuprofen is the most appropriate first-line acute treatment. This clinical presentation is classic for tension-type headache (TTH), not migraine, and the treatment approach differs fundamentally between these two conditions.
Clinical Reasoning: This is Tension-Type Headache, Not Migraine
The key diagnostic features that distinguish this as TTH rather than migraine include:
- Bilateral location (migraine is typically unilateral)
- "Tight band" quality (pressure/tightness is pathognomonic for TTH)
- Moderate intensity (not the severe, disabling pain typical of migraine)
- No mention of associated symptoms (no nausea, photophobia, phonophobia, or aura)
- Frequent occurrence (2-3 times per week suggests episodic TTH)
Evidence-Based Treatment Selection
Why Ibuprofen is Correct
NSAIDs like ibuprofen (400-800 mg) are first-line therapy for acute episodic tension-type headache 1, 2. A comprehensive network meta-analysis found that ibuprofen demonstrated superior efficacy for TTH with high-quality evidence, ranking among the top two treatment options alongside diclofenac-K 2. The recommended dosing is 400-800 mg, with the evidence showing clear superiority over placebo for achieving pain freedom at 2 hours 3, 1.
Why the Other Options are Incorrect
Sumatriptan, dihydroergotamine, and lasmiditan are all migraine-specific medications and have no role in treating tension-type headache:
Sumatriptan (and all triptans) are 5-HT1B/D receptor agonists specifically indicated for moderate to severe migraine 3, 4, 5. Guidelines explicitly state triptans are reserved for patients with moderate to severe migraines or those unresponsive to NSAIDs 3. The FDA labeling confirms sumatriptan is indicated only for acute migraine treatment, not other headache types 5.
Dihydroergotamine (DHE) is an ergot alkaloid used specifically for migraine treatment 3, 4. It works through similar mechanisms as triptans and has no established role in TTH management.
Lasmiditan is a 5-HT1F agonist approved specifically for acute migraine treatment 6, 7. The 2025 ACP guideline positions lasmiditan as a last-line option even for migraine—only for patients who have failed all other treatments including triptans, NSAIDs, and gepants 6.
Important Clinical Considerations
Dosing and Administration
- Start with ibuprofen 400-800 mg at headache onset 3, 1
- Maximum daily dose: 2.4 g per day 3
- Take early in the headache episode for optimal efficacy 3
Critical Pitfall: Medication Overuse Headache
Monitor closely for medication overuse headache, which can develop with NSAID use ≥15 days per month 6, 5. Given this patient's frequency (2-3 times per week = 8-12 times per month), he is approaching but not yet at high risk. However, counsel him about:
- Limiting acute medication use to avoid chronification 3, 8
- Tracking headache frequency and medication use 4
- Considering preventive therapy if frequency increases or acute treatment becomes insufficient
When to Reassess
If this patient's headaches:
- Increase in frequency (approaching daily or chronic pattern)
- Change character (become unilateral, throbbing, or associated with nausea/photophobia)
- Fail to respond adequately to ibuprofen after appropriate trials
Then reassessment for possible migraine or consideration of preventive therapy would be warranted 4, 1.
Contraindications to Monitor
Avoid ibuprofen in patients with:
- Aspirin/NSAID-induced asthma
- Active GI bleeding or ulcer disease
- Severe renal impairment 3
The other medications listed carry significantly more serious contraindications, particularly the migraine-specific agents which are contraindicated in patients with cardiovascular disease, uncontrolled hypertension, and various vascular conditions 3, 5—making them inappropriate even if this were migraine.